Research use only. The materials discussed on this page are sold exclusively for in vitro laboratory research. They are not for human or veterinary use, and nothing here is medical advice or a claim of benefit. Animal-model and clinical data are mentioned only as cited published literature.
Ipamorelin and CJC-1295 are two growth hormone (GH) secretagogues commonly studied in endocrinology research. Their mechanisms of action are complementary: Ipamorelin mimics ghrelin (GHRP), while CJC-1295 is a GHRH analog. This comparison analyzes their pharmacological profiles for in vitro research and preclinical models.
The two compounds
- Ipamorelin — view the Ipamorelin research product page
- CJC-1295 — view the CJC-1295 research product page
Comparison table
| Property | Ipamorelin | CJC-1295 |
|---|---|---|
| Class | GHRP (Growth Hormone Releasing Peptide) — ghrelin mimetic | GHRH (Growth Hormone Releasing Hormone) analog |
| Target receptor | GHSR-1a (Growth Hormone Secretagogue Receptor) | GHRHR (Growth Hormone Releasing Hormone Receptor) |
| Selectivity | Highly selective — no cortisol/prolactin stimulation | Selective GHRH-R |
| Half-life | ~2 hours | ~30 min (without DAC) / ~8 days (with DAC) |
| Structure | Synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) | Modified GHRH(1-29) analog, 29 amino acids (with or without Drug Affinity Complex) |
| Pulsed GH peak | Short and intense (mimics natural pulsatility) | Sustained (CJC-1295 DAC) — albumin reservoir |
| Research applications | GH pulsatility studies, somatotropic aging | Prolonged GH exposure studies, lipolysis |
| Synergy | Frequently combined with CJC-1295 in research literature | Frequently combined with GHRP (Ipamorelin) |
| Purity documentation | Batch CoA (HPLC) | Batch CoA (HPLC) |
Research contexts
Literature contexts for Ipamorelin
Studies on natural GH pulsatility, somatotropic aging models, research requiring a secretagogue without effects on cortisol/prolactin.
Literature contexts for CJC-1295
Studies requiring prolonged GH exposure (DAC), lipolysis and lean mass models, chronic IGF-1 research. Without DAC: pulsed protocols.
Mechanisms of action
Ipamorelin
Ipamorelin activates the pituitary GHSR-1a receptor (the ghrelin receptor), stimulating GH release from somatotropic cells. Its high selectivity avoids adverse effects on prolactin, cortisol, and ACTH, unlike first-generation GHRPs (GHRP-2, GHRP-6).
CJC-1295
CJC-1295 is an endogenous GHRH analog modified to resist DPP-IV degradation. The DAC (Drug Affinity Complex) version includes an MPA group that covalently binds to serum albumin, extending the half-life to several days. The non-DAC version retains short kinetics similar to natural GHRH.
Combined research context
In the literature, Ipamorelin + CJC-1295 (without DAC) is a classic research protocol: their mechanisms (GHRP + GHRH) are synergistic, mimicking the physiological regulation of GH. This combination is studied in aging models, somatotropic deficit, and GH/IGF-1 axis research.
Related research products
Axion Research Peptides supplies research-grade peptides for in vitro use, with a batch certificate of analysis. Browse Ipamorelin, CJC-1295 or the full research catalog.
Frequently asked questions
CJC-1295 with or without DAC: what’s the difference?
DAC (Drug Affinity Complex) extends the half-life from minutes to several days via covalent binding to albumin. Without DAC, CJC-1295 has short and pulsed kinetics (~30 min), like natural GHRH. With DAC, GH exposure is continuous (~8 days).
Why combine Ipamorelin and CJC-1295?
Their mechanisms are complementary: Ipamorelin stimulates GHSR-1a (mimics ghrelin) and CJC-1295 activates GHRHR (mimics GHRH). The combination reproduces the physiological pulsatile regulation of GH with greater amplitude.
Does Ipamorelin stimulate cortisol?
No — Ipamorelin is highly selective for GHSR-1a and has no significant effect on cortisol, prolactin, or ACTH, unlike first-generation GHRPs.
Which has the longest half-life?
CJC-1295 with DAC: ~8 days. CJC-1295 without DAC: ~30 min. Ipamorelin: ~2 hours. Choice depends on the research protocol (pulsed vs sustained exposure).
Are these peptides approved in the USA?
No — neither Ipamorelin nor CJC-1295 is approved by the FDA, EMA, or MHRA for clinical use. Available only for in vitro scientific research.
Scientific references
- Raun K et al., 1998 — Ipamorelin GH selectivity, Eur J Endocrinol.
- Teichman SL et al., 2006 — CJC-1295 pharmacokinetics, J Clin Endocrinol Metab.
Regulatory disclaimer
The peptides discussed in this comparison are not approved by the FDA, EMA, MHRA, or any regulatory agency for human or veterinary clinical use, except where a specific approved product is named (for example, tesamorelin as Egrifta). They are sold by Axion Research Peptides exclusively for in vitro scientific research. This page summarizes published literature and is neither medical advice nor a recommendation for clinical use.
